美通社

2026-02-25 22:00

Discovery linking gut bacteria to cancer treatment wins the Bial Award in Biomedicine and earns €350,000 prize

A study published in Science reveals that a healthy gut microbiota can enhance the efficacy of immunotherapy used to treat cancer, while antibiotics may impair its effect by reducing intestinal microbiota diversity.

PORTO, Portugal, Feb. 25, 2026 /PRNewswire/ -- An international consortium of 48 researchers from institutions in France, Sweden, and the United States has won the 2025 edition of the Bial Award in Biomedicine, a €350,000 prize promoted by the Bial Foundation to recognise a published work of exceptional quality and scientific relevance in the field of biomedicine.

Lead researchers of the winning team of the Bial Award in Biomedicine 2025 promoted by the Bial Foundation.
Lead researchers of the winning team of the Bial Award in Biomedicine 2025 promoted by the Bial Foundation.

The winning study, Gut microbiome influences efficacy of PD‑1–based immunotherapy against epithelial tumors, is led by research duo Laurence Zitvogel (Gustave Roussy and Paris-Saclay University) and Guido Kroemer (Gustave Roussy and Paris Cité University), internationally renowned French academics.

The awarded research documents one of the most significant recent advances in the treatment of several types of cancer, as it establishes that the gut microbiome - the collection of bacteria residing in the human intestine - plays a decisive role in the effectiveness of immunotherapy.

Immunotherapy has revolutionised oncology by enabling the immune system to recognise tumour cells once again and attack them, saving many patients who previously had no effective therapeutic alternatives. However, over half of patients develop resistance to these therapies, leading to disease recurrence for reasons that are until now poorly understood. The distinguished study demonstrates that the gut microbiome plays a central role in this resistance and that its modulation can significantly improve treatment response and patient survival.

The authors show that the use of antibiotics can negatively impact the effectiveness of immunotherapy by reducing gut microbiota diversity. Analysis of cancer patients revealed that greater bacterial diversity is associated with better clinical outcomes. The study also identified specific gut bacterial species consistently associated with more favourable treatment responses.

The study was published in Science in 2018 and has already more than 5,800 scientific citations.

The 2025 edition of the Award received 58 nominations from 18 countries, covering areas such as cancer, infectious diseases, and neurodegenerative disorders. Previous editions distinguished research, later receiving prestigious international scientific prizes. Notably, two of the scientists who received the Bial Award in 2021, Katalin Karikó and Drew Weissman, were awarded the 2023 Nobel Prize in Physiology or Medicine for their discoveries that enabled the development of effective mRNA-based vaccines to prevent COVID ‑ 19.

 

source: Bial Foundation

獨家優惠【etnet x 環球海產】用戶專享全場95折,特價貨品更可折上折。立即使用優惠代碼【ETN1WWS】,選購五星級酒店級海鮮► 立即瀏覽

人氣文章
財經新聞
評論
專題
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

etnet初心不變 風雨無阻 與你並肩投資路,立即加入成為etnet YouTube頻道會員!

獨家優惠【etnet x 環球海產】 用戶專享全場95折,特價貨品更可折上折,立即選購五星級酒店御用海鮮!

樂本健 x etnet健康網購 | 購物滿額即送免費禮品

說說心理話

2026-27年度財政預算案

大國博弈

關稅戰

理財秘笈

Wonder in Art

北上食買玩

香港周圍遊

山今養生智慧

輕鬆護老

照顧者 情緒健康